查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867571

液态生物检体产品：全球市场份额和排名、总收入和需求预测（2025-2031年）

Liquid Biopsy Products - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球液态生物检体产品市场预计在 2024 年达到 51.42 亿美元，预计到 2031 年将达到 114.49 亿美元，2025 年至 2031 年的复合年增长率为 12.4%。

液态生物检体产品是一种体外诊断医疗器械，可非侵入性分析血液、尿液和其他医疗设备中的生物标记物，例如循环肿瘤DNA（ctDNA）、循环性肿瘤细胞（CTC）和外泌体，用于癌症筛检、诊断、治疗后续观察和復发预测。这些产品涵盖检体采集、储存、核酸提取、标靶检测和数据解读等关键流程。与传统组织切片检查相比，液态生物检体在安全性、可重复性和对多种癌症类型的适用性方面具有优势。液体活检在临床应用中日益普及，并在精准医疗和个人化医疗领域展现出巨大的潜力。

全球精准医疗的快速发展和癌症发生率的不断攀升，为液态生物检体的应用奠定了坚实的基础。世界各地的医疗系统正在加速将液态生物检体整合到癌症筛检和标靶治疗流程中。次世代定序（NGS）成本的下降以及人工智慧（AI）带来的分析能力提升，正推动液体活检产品进入多癌种检测和多中心临床检验。

儘管液态生物检体技术日趋成熟，但在平衡灵敏度和特异性方面仍面临挑战，尤其是在癌症早期检测领域。上游和下游环节中样本处理和试剂品质标准的不一致，使得临床应用复杂化。与隐私权和生物伦理相关的监管障碍仍然是全球广泛应用的主要阻碍。根据仲介分析，目前大部分收入仍来自研究级订单，要实现更广泛的临床应用并建立健保报销机制，还需要进一步的研发。

液态生物检体的需求正迅速从研究用途转向常规临床应用。在肺癌、乳癌和大肠癌等高发生率癌症中，治疗反应监测和早期復发检测正推动医院的采购。生技公司与医院之间的合作日益深入，联合实验室和多中心合作研究已成为常态。年度报告也反映出患者对非侵入性检测的意识和偏好不断增强，推动了产品在家庭检测和行动诊断情境中的应用。

本报告旨在对全球液态生物检体产品市场进行全面分析，重点关注总收入、市场份额和主要企业的排名，并按地区/国家、产品类型和应用进行分析。

本报告以销售收入为指标，对液态生物检体产品市场规模、估算和预测进行了阐述，以 2024 年为基准年，并涵盖了 2020 年至 2031 年的历史数据和预测数据。报告运用定量和定性分析方法，帮助读者制定液态生物检体产品业务/成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Roche
  • Illumina
  • Qiagen
  • Guardant Health
  • MDxHealth
  • Pathway Genomics
  • NeoGenomics Laboraories
  • Novogen
  • BGI
  • Myriad Genetics
  • Adaptive Biotechnologies
  • Biocept
  • Angle plc
  • Exact Sciences
  • Natera
  • Freenome
  • Aide Bio
  • Thermo Fisher Scientific

按类型分類的细分市场

  • CTC
  • ctDNA
  • 外泌体

按样本分段

  • 血液样本
  • 尿液检体
  • 其他的

应用领域

  • 医院和诊所
  • 外部检查机构
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Liquid Biopsy Products was estimated to be worth US$ 5142 million in 2024 and is forecast to a readjusted size of US$ 11449 million by 2031 with a CAGR of 12.4% during the forecast period 2025-2031.

Liquid biopsy products refer to a category of in vitro diagnostic tools that non-invasively analyze biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes from blood, urine, or other body fluids for cancer screening, diagnosis, treatment monitoring, and recurrence prediction. These products span key steps such as sample collection, preservation, nucleic acid extraction, target detection, and data interpretation. Compared to traditional tissue biopsy, liquid biopsy offers advantages in safety, repeatability, and applicability across various cancer types, making it increasingly adopted in clinical settings and showing great potential in precision and personalized medicine.

The rapid global advancement of precision medicine and rising cancer incidence form a strong foundation for liquid biopsy adoption. National healthcare systems are increasingly incorporating liquid biopsy into cancer screening and targeted therapy workflows. The declining cost of next-generation sequencing (NGS) and enhanced interpretation capabilities through AI are accelerating product entry into multi-cancer detection and multicenter clinical validation.

Despite increasing technological maturity, liquid biopsy still faces challenges in balancing sensitivity and specificity, especially for early-stage cancer detection. Non-uniform standards in sample processing and reagent quality across upstream and downstream components complicate clinical translation. Regulatory hurdles around privacy and bioethics remain significant barriers for global expansion. Broker analyses highlight that most revenue still stems from research-grade orders, and wider clinical adoption and reimbursement pathways require further development.

Demand for liquid biopsy is rapidly shifting from research use to routine clinical applications. Monitoring therapeutic response and early relapse detection in high-incidence cancers-such as lung, breast, and colorectal-are driving hospital procurement. Collaboration between biotech companies and hospitals is deepening, with joint labs and multicenter studies becoming the norm. Annual reports also reflect growing patient awareness and preference for non-invasive testing, spurring product expansion into home-testing and mobile diagnostic scenarios.

This report aims to provide a comprehensive presentation of the global market for Liquid Biopsy Products, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Liquid Biopsy Products by region & country, by Type, and by Application.

The Liquid Biopsy Products market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liquid Biopsy Products.

Market Segmentation

By Company

  • Roche
  • Illumina
  • Qiagen
  • Guardant Health
  • MDxHealth
  • Pathway Genomics
  • NeoGenomics Laboraories
  • Novogen
  • BGI
  • Myriad Genetics
  • Adaptive Biotechnologies
  • Biocept
  • Angle plc
  • Exact Sciences
  • Natera
  • Freenome
  • Aide Bio
  • Thermo Fisher Scientific

Segment by Type

  • CTCs
  • ctDNA
  • Exosomes

Segment by Sample

  • Blood Sample
  • Urine Sample
  • Other

Segment by Application

  • Hospitals and Clinics
  • Third-party Laboratories
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Liquid Biopsy Products company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Liquid Biopsy Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Liquid Biopsy Products in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Liquid Biopsy Products Product Introduction
  • 1.2 Global Liquid Biopsy Products Market Size Forecast (2020-2031)
  • 1.3 Liquid Biopsy Products Market Trends & Drivers
    • 1.3.1 Liquid Biopsy Products Industry Trends
    • 1.3.2 Liquid Biopsy Products Market Drivers & Opportunity
    • 1.3.3 Liquid Biopsy Products Market Challenges
    • 1.3.4 Liquid Biopsy Products Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Liquid Biopsy Products Players Revenue Ranking (2024)
  • 2.2 Global Liquid Biopsy Products Revenue by Company (2020-2025)
  • 2.3 Key Companies Liquid Biopsy Products Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Liquid Biopsy Products Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Liquid Biopsy Products
  • 2.6 Liquid Biopsy Products Market Competitive Analysis
    • 2.6.1 Liquid Biopsy Products Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Liquid Biopsy Products Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liquid Biopsy Products as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 CTCs
    • 3.1.2 ctDNA
    • 3.1.3 Exosomes
  • 3.2 Global Liquid Biopsy Products Sales Value by Type
    • 3.2.1 Global Liquid Biopsy Products Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Liquid Biopsy Products Sales Value, by Type (2020-2031)
    • 3.2.3 Global Liquid Biopsy Products Sales Value, by Type (%) (2020-2031)

4 Segmentation by Sample

  • 4.1 Introduction by Sample
    • 4.1.1 Blood Sample
    • 4.1.2 Urine Sample
    • 4.1.3 Other
  • 4.2 Global Liquid Biopsy Products Sales Value by Sample
    • 4.2.1 Global Liquid Biopsy Products Sales Value by Sample (2020 VS 2024 VS 2031)
    • 4.2.2 Global Liquid Biopsy Products Sales Value, by Sample (2020-2031)
    • 4.2.3 Global Liquid Biopsy Products Sales Value, by Sample (%) (2020-2031)

5 Segmentation by Application

  • 5.1 Introduction by Application
    • 5.1.1 Hospitals and Clinics
    • 5.1.2 Third-party Laboratories
    • 5.1.3 Other
  • 5.2 Global Liquid Biopsy Products Sales Value by Application
    • 5.2.1 Global Liquid Biopsy Products Sales Value by Application (2020 VS 2024 VS 2031)
    • 5.2.2 Global Liquid Biopsy Products Sales Value, by Application (2020-2031)
    • 5.2.3 Global Liquid Biopsy Products Sales Value, by Application (%) (2020-2031)

6 Segmentation by Region

  • 6.1 Global Liquid Biopsy Products Sales Value by Region
    • 6.1.1 Global Liquid Biopsy Products Sales Value by Region: 2020 VS 2024 VS 2031
    • 6.1.2 Global Liquid Biopsy Products Sales Value by Region (2020-2025)
    • 6.1.3 Global Liquid Biopsy Products Sales Value by Region (2026-2031)
    • 6.1.4 Global Liquid Biopsy Products Sales Value by Region (%), (2020-2031)
  • 6.2 North America
    • 6.2.1 North America Liquid Biopsy Products Sales Value, 2020-2031
    • 6.2.2 North America Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
  • 6.3 Europe
    • 6.3.1 Europe Liquid Biopsy Products Sales Value, 2020-2031
    • 6.3.2 Europe Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Liquid Biopsy Products Sales Value, 2020-2031
    • 6.4.2 Asia Pacific Liquid Biopsy Products Sales Value by Region (%), 2024 VS 2031
  • 6.5 South America
    • 6.5.1 South America Liquid Biopsy Products Sales Value, 2020-2031
    • 6.5.2 South America Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
  • 6.6 Middle East & Africa
    • 6.6.1 Middle East & Africa Liquid Biopsy Products Sales Value, 2020-2031
    • 6.6.2 Middle East & Africa Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031

7 Segmentation by Key Countries/Regions

  • 7.1 Key Countries/Regions Liquid Biopsy Products Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 7.2 Key Countries/Regions Liquid Biopsy Products Sales Value, 2020-2031
  • 7.3 United States
    • 7.3.1 United States Liquid Biopsy Products Sales Value, 2020-2031
    • 7.3.2 United States Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
    • 7.3.3 United States Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
  • 7.4 Europe
    • 7.4.1 Europe Liquid Biopsy Products Sales Value, 2020-2031
    • 7.4.2 Europe Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
    • 7.4.3 Europe Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
  • 7.5 China
    • 7.5.1 China Liquid Biopsy Products Sales Value, 2020-2031
    • 7.5.2 China Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
    • 7.5.3 China Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
  • 7.6 Japan
    • 7.6.1 Japan Liquid Biopsy Products Sales Value, 2020-2031
    • 7.6.2 Japan Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
    • 7.6.3 Japan Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
  • 7.7 South Korea
    • 7.7.1 South Korea Liquid Biopsy Products Sales Value, 2020-2031
    • 7.7.2 South Korea Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
    • 7.7.3 South Korea Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
  • 7.8 Southeast Asia
    • 7.8.1 Southeast Asia Liquid Biopsy Products Sales Value, 2020-2031
    • 7.8.2 Southeast Asia Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
    • 7.8.3 Southeast Asia Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
  • 7.9 India
    • 7.9.1 India Liquid Biopsy Products Sales Value, 2020-2031
    • 7.9.2 India Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
    • 7.9.3 India Liquid Biopsy Products Sales Value by Application, 2024 VS 2031

8 Company Profiles

  • 8.1 Roche
    • 8.1.1 Roche Profile
    • 8.1.2 Roche Main Business
    • 8.1.3 Roche Liquid Biopsy Products Products, Services and Solutions
    • 8.1.4 Roche Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.1.5 Roche Recent Developments
  • 8.2 Illumina
    • 8.2.1 Illumina Profile
    • 8.2.2 Illumina Main Business
    • 8.2.3 Illumina Liquid Biopsy Products Products, Services and Solutions
    • 8.2.4 Illumina Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.2.5 Illumina Recent Developments
  • 8.3 Qiagen
    • 8.3.1 Qiagen Profile
    • 8.3.2 Qiagen Main Business
    • 8.3.3 Qiagen Liquid Biopsy Products Products, Services and Solutions
    • 8.3.4 Qiagen Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.3.5 Qiagen Recent Developments
  • 8.4 Guardant Health
    • 8.4.1 Guardant Health Profile
    • 8.4.2 Guardant Health Main Business
    • 8.4.3 Guardant Health Liquid Biopsy Products Products, Services and Solutions
    • 8.4.4 Guardant Health Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.4.5 Guardant Health Recent Developments
  • 8.5 MDxHealth
    • 8.5.1 MDxHealth Profile
    • 8.5.2 MDxHealth Main Business
    • 8.5.3 MDxHealth Liquid Biopsy Products Products, Services and Solutions
    • 8.5.4 MDxHealth Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.5.5 MDxHealth Recent Developments
  • 8.6 Pathway Genomics
    • 8.6.1 Pathway Genomics Profile
    • 8.6.2 Pathway Genomics Main Business
    • 8.6.3 Pathway Genomics Liquid Biopsy Products Products, Services and Solutions
    • 8.6.4 Pathway Genomics Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.6.5 Pathway Genomics Recent Developments
  • 8.7 NeoGenomics Laboraories
    • 8.7.1 NeoGenomics Laboraories Profile
    • 8.7.2 NeoGenomics Laboraories Main Business
    • 8.7.3 NeoGenomics Laboraories Liquid Biopsy Products Products, Services and Solutions
    • 8.7.4 NeoGenomics Laboraories Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.7.5 NeoGenomics Laboraories Recent Developments
  • 8.8 Novogen
    • 8.8.1 Novogen Profile
    • 8.8.2 Novogen Main Business
    • 8.8.3 Novogen Liquid Biopsy Products Products, Services and Solutions
    • 8.8.4 Novogen Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.8.5 Novogen Recent Developments
  • 8.9 BGI
    • 8.9.1 BGI Profile
    • 8.9.2 BGI Main Business
    • 8.9.3 BGI Liquid Biopsy Products Products, Services and Solutions
    • 8.9.4 BGI Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.9.5 BGI Recent Developments
  • 8.10 Myriad Genetics
    • 8.10.1 Myriad Genetics Profile
    • 8.10.2 Myriad Genetics Main Business
    • 8.10.3 Myriad Genetics Liquid Biopsy Products Products, Services and Solutions
    • 8.10.4 Myriad Genetics Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.10.5 Myriad Genetics Recent Developments
  • 8.11 Adaptive Biotechnologies
    • 8.11.1 Adaptive Biotechnologies Profile
    • 8.11.2 Adaptive Biotechnologies Main Business
    • 8.11.3 Adaptive Biotechnologies Liquid Biopsy Products Products, Services and Solutions
    • 8.11.4 Adaptive Biotechnologies Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.11.5 Adaptive Biotechnologies Recent Developments
  • 8.12 Biocept
    • 8.12.1 Biocept Profile
    • 8.12.2 Biocept Main Business
    • 8.12.3 Biocept Liquid Biopsy Products Products, Services and Solutions
    • 8.12.4 Biocept Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.12.5 Biocept Recent Developments
  • 8.13 Angle plc
    • 8.13.1 Angle plc Profile
    • 8.13.2 Angle plc Main Business
    • 8.13.3 Angle plc Liquid Biopsy Products Products, Services and Solutions
    • 8.13.4 Angle plc Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.13.5 Angle plc Recent Developments
  • 8.14 Exact Sciences
    • 8.14.1 Exact Sciences Profile
    • 8.14.2 Exact Sciences Main Business
    • 8.14.3 Exact Sciences Liquid Biopsy Products Products, Services and Solutions
    • 8.14.4 Exact Sciences Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.14.5 Exact Sciences Recent Developments
  • 8.15 Natera
    • 8.15.1 Natera Profile
    • 8.15.2 Natera Main Business
    • 8.15.3 Natera Liquid Biopsy Products Products, Services and Solutions
    • 8.15.4 Natera Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.15.5 Natera Recent Developments
  • 8.16 Freenome
    • 8.16.1 Freenome Profile
    • 8.16.2 Freenome Main Business
    • 8.16.3 Freenome Liquid Biopsy Products Products, Services and Solutions
    • 8.16.4 Freenome Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.16.5 Freenome Recent Developments
  • 8.17 Aide Bio
    • 8.17.1 Aide Bio Profile
    • 8.17.2 Aide Bio Main Business
    • 8.17.3 Aide Bio Liquid Biopsy Products Products, Services and Solutions
    • 8.17.4 Aide Bio Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.17.5 Aide Bio Recent Developments
  • 8.18 Thermo Fisher Scientific
    • 8.18.1 Thermo Fisher Scientific Profile
    • 8.18.2 Thermo Fisher Scientific Main Business
    • 8.18.3 Thermo Fisher Scientific Liquid Biopsy Products Products, Services and Solutions
    • 8.18.4 Thermo Fisher Scientific Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
    • 8.18.5 Thermo Fisher Scientific Recent Developments

9 Industry Chain Analysis

  • 9.1 Liquid Biopsy Products Industrial Chain
  • 9.2 Liquid Biopsy Products Upstream Analysis
    • 9.2.1 Key Raw Materials
    • 9.2.2 Raw Materials Key Suppliers
    • 9.2.3 Manufacturing Cost Structure
  • 9.3 Midstream Analysis
  • 9.4 Downstream Analysis (Customers Analysis)
  • 9.5 Sales Model and Sales Channels
    • 9.5.1 Liquid Biopsy Products Sales Model
    • 9.5.2 Sales Channel
    • 9.5.3 Liquid Biopsy Products Distributors

10 Research Findings and Conclusion

11 Appendix

  • 11.1 Research Methodology
    • 11.1.1 Methodology/Research Approach
      • 11.1.1.1 Research Programs/Design
      • 11.1.1.2 Market Size Estimation
      • 11.1.1.3 Market Breakdown and Data Triangulation
    • 11.1.2 Data Source
      • 11.1.2.1 Secondary Sources
      • 11.1.2.2 Primary Sources
  • 11.2 Author Details
  • 11.3 Disclaimer

List of Tables

  • Table 1. Liquid Biopsy Products Market Trends
  • Table 2. Liquid Biopsy Products Market Drivers & Opportunity
  • Table 3. Liquid Biopsy Products Market Challenges
  • Table 4. Liquid Biopsy Products Market Restraints
  • Table 5. Global Liquid Biopsy Products Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Liquid Biopsy Products Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Liquid Biopsy Products Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Liquid Biopsy Products Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Liquid Biopsy Products
  • Table 10. Global Liquid Biopsy Products Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liquid Biopsy Products as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Liquid Biopsy Products Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Liquid Biopsy Products Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Liquid Biopsy Products Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Liquid Biopsy Products Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Liquid Biopsy Products Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Liquid Biopsy Products Sales Value by Sample: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Liquid Biopsy Products Sales Value by Sample (2020-2025) & (US$ Million)
  • Table 20. Global Liquid Biopsy Products Sales Value by Sample (2026-2031) & (US$ Million)
  • Table 21. Global Liquid Biopsy Products Sales Market Share in Value by Sample (2020-2025)
  • Table 22. Global Liquid Biopsy Products Sales Market Share in Value by Sample (2026-2031)
  • Table 23. Global Liquid Biopsy Products Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 24. Global Liquid Biopsy Products Sales Value by Application (2020-2025) & (US$ Million)
  • Table 25. Global Liquid Biopsy Products Sales Value by Application (2026-2031) & (US$ Million)
  • Table 26. Global Liquid Biopsy Products Sales Market Share in Value by Application (2020-2025)
  • Table 27. Global Liquid Biopsy Products Sales Market Share in Value by Application (2026-2031)
  • Table 28. Global Liquid Biopsy Products Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 29. Global Liquid Biopsy Products Sales Value by Region (2020-2025) & (US$ Million)
  • Table 30. Global Liquid Biopsy Products Sales Value by Region (2026-2031) & (US$ Million)
  • Table 31. Global Liquid Biopsy Products Sales Value by Region (2020-2025) & (%)
  • Table 32. Global Liquid Biopsy Products Sales Value by Region (2026-2031) & (%)
  • Table 33. Key Countries/Regions Liquid Biopsy Products Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 34. Key Countries/Regions Liquid Biopsy Products Sales Value, (2020-2025) & (US$ Million)
  • Table 35. Key Countries/Regions Liquid Biopsy Products Sales Value, (2026-2031) & (US$ Million)
  • Table 36. Roche Basic Information List
  • Table 37. Roche Description and Business Overview
  • Table 38. Roche Liquid Biopsy Products Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Liquid Biopsy Products Business of Roche (2020-2025)
  • Table 40. Roche Recent Developments
  • Table 41. Illumina Basic Information List
  • Table 42. Illumina Description and Business Overview
  • Table 43. Illumina Liquid Biopsy Products Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Liquid Biopsy Products Business of Illumina (2020-2025)
  • Table 45. Illumina Recent Developments
  • Table 46. Qiagen Basic Information List
  • Table 47. Qiagen Description and Business Overview
  • Table 48. Qiagen Liquid Biopsy Products Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Liquid Biopsy Products Business of Qiagen (2020-2025)
  • Table 50. Qiagen Recent Developments
  • Table 51. Guardant Health Basic Information List
  • Table 52. Guardant Health Description and Business Overview
  • Table 53. Guardant Health Liquid Biopsy Products Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Liquid Biopsy Products Business of Guardant Health (2020-2025)
  • Table 55. Guardant Health Recent Developments
  • Table 56. MDxHealth Basic Information List
  • Table 57. MDxHealth Description and Business Overview
  • Table 58. MDxHealth Liquid Biopsy Products Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Liquid Biopsy Products Business of MDxHealth (2020-2025)
  • Table 60. MDxHealth Recent Developments
  • Table 61. Pathway Genomics Basic Information List
  • Table 62. Pathway Genomics Description and Business Overview
  • Table 63. Pathway Genomics Liquid Biopsy Products Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Liquid Biopsy Products Business of Pathway Genomics (2020-2025)
  • Table 65. Pathway Genomics Recent Developments
  • Table 66. NeoGenomics Laboraories Basic Information List
  • Table 67. NeoGenomics Laboraories Description and Business Overview
  • Table 68. NeoGenomics Laboraories Liquid Biopsy Products Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Liquid Biopsy Products Business of NeoGenomics Laboraories (2020-2025)
  • Table 70. NeoGenomics Laboraories Recent Developments
  • Table 71. Novogen Basic Information List
  • Table 72. Novogen Description and Business Overview
  • Table 73. Novogen Liquid Biopsy Products Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Liquid Biopsy Products Business of Novogen (2020-2025)
  • Table 75. Novogen Recent Developments
  • Table 76. BGI Basic Information List
  • Table 77. BGI Description and Business Overview
  • Table 78. BGI Liquid Biopsy Products Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Liquid Biopsy Products Business of BGI (2020-2025)
  • Table 80. BGI Recent Developments
  • Table 81. Myriad Genetics Basic Information List
  • Table 82. Myriad Genetics Description and Business Overview
  • Table 83. Myriad Genetics Liquid Biopsy Products Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Liquid Biopsy Products Business of Myriad Genetics (2020-2025)
  • Table 85. Myriad Genetics Recent Developments
  • Table 86. Adaptive Biotechnologies Basic Information List
  • Table 87. Adaptive Biotechnologies Description and Business Overview
  • Table 88. Adaptive Biotechnologies Liquid Biopsy Products Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Liquid Biopsy Products Business of Adaptive Biotechnologies (2020-2025)
  • Table 90. Adaptive Biotechnologies Recent Developments
  • Table 91. Biocept Basic Information List
  • Table 92. Biocept Description and Business Overview
  • Table 93. Biocept Liquid Biopsy Products Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Liquid Biopsy Products Business of Biocept (2020-2025)
  • Table 95. Biocept Recent Developments
  • Table 96. Angle plc Basic Information List
  • Table 97. Angle plc Description and Business Overview
  • Table 98. Angle plc Liquid Biopsy Products Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Liquid Biopsy Products Business of Angle plc (2020-2025)
  • Table 100. Angle plc Recent Developments
  • Table 101. Exact Sciences Basic Information List
  • Table 102. Exact Sciences Description and Business Overview
  • Table 103. Exact Sciences Liquid Biopsy Products Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Liquid Biopsy Products Business of Exact Sciences (2020-2025)
  • Table 105. Exact Sciences Recent Developments
  • Table 106. Natera Basic Information List
  • Table 107. Natera Description and Business Overview
  • Table 108. Natera Liquid Biopsy Products Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Liquid Biopsy Products Business of Natera (2020-2025)
  • Table 110. Natera Recent Developments
  • Table 111. Freenome Basic Information List
  • Table 112. Freenome Description and Business Overview
  • Table 113. Freenome Liquid Biopsy Products Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Liquid Biopsy Products Business of Freenome (2020-2025)
  • Table 115. Freenome Recent Developments
  • Table 116. Aide Bio Basic Information List
  • Table 117. Aide Bio Description and Business Overview
  • Table 118. Aide Bio Liquid Biopsy Products Products, Services and Solutions
  • Table 119. Revenue (US$ Million) in Liquid Biopsy Products Business of Aide Bio (2020-2025)
  • Table 120. Aide Bio Recent Developments
  • Table 121. Thermo Fisher Scientific Basic Information List
  • Table 122. Thermo Fisher Scientific Description and Business Overview
  • Table 123. Thermo Fisher Scientific Liquid Biopsy Products Products, Services and Solutions
  • Table 124. Revenue (US$ Million) in Liquid Biopsy Products Business of Thermo Fisher Scientific (2020-2025)
  • Table 125. Thermo Fisher Scientific Recent Developments
  • Table 126. Key Raw Materials Lists
  • Table 127. Raw Materials Key Suppliers Lists
  • Table 128. Liquid Biopsy Products Downstream Customers
  • Table 129. Liquid Biopsy Products Distributors List
  • Table 130. Research Programs/Design for This Report
  • Table 131. Key Data Information from Secondary Sources
  • Table 132. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Liquid Biopsy Products Product Picture
  • Figure 2. Global Liquid Biopsy Products Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Liquid Biopsy Products Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Liquid Biopsy Products Report Years Considered
  • Figure 5. Global Liquid Biopsy Products Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Liquid Biopsy Products Revenue in 2024
  • Figure 7. Liquid Biopsy Products Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. CTCs Picture
  • Figure 9. ctDNA Picture
  • Figure 10. Exosomes Picture
  • Figure 11. Global Liquid Biopsy Products Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Liquid Biopsy Products Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Blood Sample Picture
  • Figure 14. Urine Sample Picture
  • Figure 15. Other Picture
  • Figure 16. Global Liquid Biopsy Products Sales Value by Sample (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Liquid Biopsy Products Sales Value Market Share by Sample, 2024 & 2031
  • Figure 18. Product Picture of Hospitals and Clinics
  • Figure 19. Product Picture of Third-party Laboratories
  • Figure 20. Product Picture of Other
  • Figure 21. Global Liquid Biopsy Products Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 22. Global Liquid Biopsy Products Sales Value Market Share by Application, 2024 & 2031
  • Figure 23. North America Liquid Biopsy Products Sales Value (2020-2031) & (US$ Million)
  • Figure 24. North America Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Europe Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. Europe Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Asia Pacific Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Asia Pacific Liquid Biopsy Products Sales Value by Region (%), 2024 VS 2031
  • Figure 29. South America Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. South America Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Middle East & Africa Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Middle East & Africa Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
  • Figure 33. Key Countries/Regions Liquid Biopsy Products Sales Value (%), (2020-2031)
  • Figure 34. United States Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. United States Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
  • Figure 36. United States Liquid Biopsy Products Sales Value by Application (%), 2024 VS 2031
  • Figure 37. Europe Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Europe Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
  • Figure 39. Europe Liquid Biopsy Products Sales Value by Application (%), 2024 VS 2031
  • Figure 40. China Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. China Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
  • Figure 42. China Liquid Biopsy Products Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Japan Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Japan Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Japan Liquid Biopsy Products Sales Value by Application (%), 2024 VS 2031
  • Figure 46. South Korea Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. South Korea Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
  • Figure 48. South Korea Liquid Biopsy Products Sales Value by Application (%), 2024 VS 2031
  • Figure 49. Southeast Asia Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. Southeast Asia Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
  • Figure 51. Southeast Asia Liquid Biopsy Products Sales Value by Application (%), 2024 VS 2031
  • Figure 52. India Liquid Biopsy Products Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. India Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
  • Figure 54. India Liquid Biopsy Products Sales Value by Application (%), 2024 VS 2031
  • Figure 55. Liquid Biopsy Products Industrial Chain
  • Figure 56. Liquid Biopsy Products Manufacturing Cost Structure
  • Figure 57. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 58. Bottom-up and Top-down Approaches for This Report
  • Figure 59. Data Triangulation
  • Figure 60. Key Executives Interviewed